New Cancer Vaccine Shows Striking Survival in Pancreatic and Brain Cancers

HOUSTON, TX – May 01, 2026 – In a significant development for the treatment of two of the most lethal cancers, Houston-based Diakonos Oncology has announced highly encouraging clinical data for its investigational immunotherapy, DOC1021. The personalized cancer vaccine has demonstrated remarkable survival benefits in early-stage trials for patients with glioblastoma, an aggressive brain cancer, and pancreatic cancer, with results presented at two of the nation's premier medical conferences.

The new data, unveiled at the American Association for Cancer Research (AACR) and American Academy of Neurology (AAN) 2026 annual meetings, suggest that the novel therapy can effectively awaken a patient's own immune system to fight tumors that have historically resisted such approaches. The findings provide a crucial glimmer of hope in fields of oncology desperately in need of breakthroughs.

A Beacon of Hope for Intractable Cancers

The results from the glioblastoma (GBM) expanded access program were particularly striking. All seven patients treated with DOC1021, including five newly diagnosed and two with recurrent disease, surpassed the 12-month overall survival mark. This 100% survival rate at one year stands in sharp contrast to the historical benchmark for standard of care, where only about 60% of patients typically reach this milestone. These results are consistent with a prior Phase 1 study where DOC1021 achieved an 88% 12-month survival rate. For patients with recurrent GBM, a diagnosis that often comes with a prognosis of less than a year, two individuals have now survived 18.5 and 22 months post-surgery, respectively.

Equally compelling data emerged from the Phase 1 study in pancreatic ductal adenocarcinoma (PDAC), a disease notorious for its rapid progression and poor outcomes. Among patients with operable tumors who received DOC1021, post-operative survival has stretched from approximately 20 months to a remarkable 56 months. As of March 2026, five of the seven participants remain alive, with three showing no signs of relapse. These figures are significant when compared to standard outcomes, where even after successful surgery, median survival often hovers around 20 to 24 months due to high rates of recurrence.

"Presenting clinical data at both AACR and AAN underscores the breadth of the DOC1021 platform across multiple hard-to-treat cancers with significant unmet need," said Jay Hartenbach, President and Chief Operating Officer of Diakonos Oncology, in a statement. "These findings reinforce our confidence in DOC1021 as we advance into randomized Phase 2 evaluation in GBM and continue to expand the platform's clinical potential."

Crucially, the therapy was well-tolerated in both studies. Patients primarily experienced mild, manageable side effects like flu-like symptoms or injection site reactions, with no dose-limiting toxicities observed. This favorable safety profile is a key advantage, especially for patients who are often weakened by their disease and aggressive standard treatments.

Dr. Benjamin Musher, a Professor of Medicine at Baylor College of Medicine and the pancreatic cancer study's principal investigator, highlighted the therapy's potential. "While these findings are preliminary, they suggest DOC1021 may engage the immune system in a disease historically resistant to immunotherapy, thus warranting further clinical investigation," he stated.

The Science Behind the Survival: 'Double-Loading' the Immune System

At the heart of these promising results is DOC1021's unique mechanism. It is a first-in-class, patient-derived dendritic cell therapy. Unlike off-the-shelf drugs, it is a personalized vaccine created for each individual patient.

The process begins with collecting dendritic cells, the immune system's master coordinators, from a patient's blood. In the lab, these cells are "trained" to recognize the patient's specific cancer using a proprietary 'double-loading' technique. This involves exposing the dendritic cells to two sets of instructions: the full array of proteins from the patient’s own tumor (tumor lysate) and amplified messenger RNA (mRNA) also derived from the tumor.

This double-loading approach is designed to mimic a natural viral infection, provoking a powerful and comprehensive immune response. By presenting the entire landscape of the tumor's antigens, the therapy trains the immune system's T-cells to recognize and attack cancer cells in all their diversity, potentially preventing escape by tumor variants that might otherwise evade a more narrowly focused treatment.

The clinical data confirm this mechanism is working as intended. Immune analyses from both the GBM and pancreatic cancer studies showed a significant increase in cytotoxic T-cells—the 'killer' cells that directly destroy tumor cells—as well as a boost in memory T-cells. The upregulation of markers like CD127 on T-cells is particularly important, as it indicates the creation of a long-lasting immune memory, which could be key to preventing cancer recurrence.

Notably, the DOC1021 platform does not require any genetic engineering of a patient's cells or the use of harsh pre-conditioning chemotherapy, setting it apart from some other advanced cell therapies. It is designed for simple outpatient administration, which could make it widely accessible if eventually approved.

Navigating the Path to Approval

Diakonos Oncology's progress has not gone unnoticed by regulators. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to DOC1021 for treating pancreatic cancer, GBM, and melanoma. This designation is intended to expedite the development and review of drugs that address serious conditions with high unmet medical needs. The GBM program also received Orphan Drug Designation, providing further incentives to support its development for this rare but devastating disease.

The next and most critical step for the company is to validate these early signals in larger, more rigorous trials. Diakonos is now actively enrolling patients in a randomized Phase 2 trial for newly diagnosed GBM (NCT06805305). This study will directly compare DOC1021 plus standard of care against standard of care alone, providing the high-quality evidence needed to definitively prove the therapy's benefit.

The company's pipeline also includes a Phase 1/2 study in refractory melanoma, supported by a grant from the Cancer Prevention and Research Institute of Texas (CPRIT), showcasing the platform's potential breadth.

While the journey to market is long and fraught with challenges, the data presented by Diakonos offer a compelling case for cautious optimism. In the difficult fight against glioblastoma and pancreatic cancer, where progress has been painfully slow, the results from DOC1021 represent a scientifically robust and clinically meaningful step forward. The oncology community will be watching the upcoming Phase 2 trial with great interest, hopeful that this innovative approach could one day change the standard of care.